Patent to be granted in China regarding IntelliGel
The China National Intellectual Property Administration (CNIPA) has communicated its intention to grant a new patent in China in the portfolio licensed to Redwood Pharma from Broda International LLC. A new patent will, when granted, provide patent protection in China, one of the largest markets globally, for the IntelliGel platform, which is used, inter alia, in the development of Redwood Pharmas RP101 new candidate drug.
China represents one of the largest global markets and opportunities for topical eye therapies using the IntelliGel drug delivery platform. This means that Redwood Pharma’s ophthalmology therapy RP101 soon will have protection through IntelliGel in the four major global markets: the US, EU, Japan and China.
“The value of RP101 and the IntelliGel platform will now increase, providing future commercial partners in the region protection from competitive pressures. Redwood Pharma secures the protection through an integrated IP strategy implemented by the company and by the licensor Broda International. We thank our licensing partners for their continued innovations and for continuing to seek IP protection, “ says CEO Martin Vidaeus.
IntelliGel is Redwood Pharma’s exclusive technology for delivering drug to the front of the eye with a new hydrogel based on poloxamers and water. IntelliGel is applied as eye drop and gels on contact with the eye. This transparent, lubricating, reversible thermogel can increase the bioavailability of the active substance, as the gel holds the drug in the eye for longer. This, in turn, allows for a reduction of the amount of active substance administered, a reduction in the number of doses and possible side effects related to the active substance. IntelliGel is currently used in dermatological products sold commercially in the US and China. IntelliGel can be used for prescription products as well as for OTC products.
RP101 is a novel, topical treatment for post-menopausal women suffering from chronic, moderate-to-severe dry eye disease (DED). This Phase II product candidate consists of a low-dose estrogen analog formulated in IntelliGel, a proprietary controlled-release drug delivery platform, and will be the first hormonal therapy for DED targeted to specific underlying biological mechanisms in critical tissues in and around the eye. Redwood Pharma initiated a randomized, placebo-controlled multicenter Phase II trial where the first patient was dosed in February 2019, with the last patient exiting the trial in November 2019 and topline results expected in Q1 2020. Highlights include:
- Serious unmet medical need (US$3bn global DED market) and well-defined addressable market – 7% of all post-menopausal women suffer from moderate-to-severe DED, 10m in the US & Europe alone
- Estrogen – a safe and effective API found in 500+ products sold globally. RP101 will deliver a topical, low dose to the eye
- Novel IntelliGel drug delivery platform well-suited for ophthalmic use – increases bioavailability, reduces number of doses
- Strong safety profile and efficacy data, including positive data from 2 previous Phase II trials in the US of 138 patients demonstrating safety profile and improvement of both signs and symptoms in post-menopausal women with moderate-to-severe DED
- Phase II data in Q1 2020, with GMP production established and clear path to commercialization
- Strong IP and market exclusivity
For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29
This information is information that Redwood Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at February 10, 2020.
About Redwood Pharma
Redwood Pharma develops ophthalmic products for unmet medical needs. The Company’s first project is the development of drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel the release of active substances is controlled. Through the use of IntelliGel, Redwood Pharma can also improve dosing of other established drugs. Redwood Pharma’s strength lies in formulation and early clinical development. Revenues will be generated through licensing agreements with pharmaceutical companies that have capabilities to manufacture and sell commercial products worldwide.
Redwood Pharma AB (publ.) is listed on the Spotlight Stock Market (Ticker: REDW.ST, ISIN: SE008294789).
For more information visit: www.redwoodpharma.com